Lantern Pharma Inc. — Director's Dealing 2026

Jan 13, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lantern Pharma Inc. (LTRN)
CIK: 0001763950
Period of Report: 2026-01-09

Reporting Person: Schalop Lee Troy (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-09	Stock Option (Right to Buy)	$3.49	A	25000	Acquired	2036-01-08	Common Stock (25000)	Direct
2026-01-09	Stock Option (Right to Buy)	$3.49	A	18460	Acquired	2036-01-08	Common Stock (18460)	Direct

Footnotes

F1: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026.

F2: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026.